How Tenaya Therapeutics, Inc. is positioning TN-401 against the limitations of current ARVC care
Could TN-401 change ARVC treatment strategy? Explore what Tenaya Therapeutics, Inc.’s RIDGE-1 data means for cardiac gene therapy.
What Affinia Therapeutics’ UPBEAT trial reveals about the next phase of inherited heart failure gene therapy
Affinia Therapeutics has cleared AFTX-201 for a Canadian BAG3 DCM trial. Read why the gene therapy’s design and risks matter now.
Affinia Therapeutics’ AFTX-201 Fast Track decision highlights rising interest in cardiac gene therapy
Affinia Therapeutics’ AFTX-201 wins FDA Fast Track for BAG3 cardiomyopathy. Explore what this means for cardiac gene therapy and future heart failure treatments.